Recombinant IL12B (Briakinumab Biosimilar) antibody

Catalog No. ABIN7795102

The Mouse Monoclonal anti-IL12B (Briakinumab Biosimilar) antibody (ABIN7795102) specifically detects IL12B (Briakinumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant IL12B (Briakinumab Biosimilar) antibody (ABIN7795102)

Target: IL12B (Briakinumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This IL12B (Briakinumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-IL12B (Briakinumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Briakinumab Biosimilar, IL-12 / IL-23 Monoclonal Antibody

Characteristics: What is Briakinumab Biosimilar research grade? Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn's Disease and other autoimmune and inflammatory disorders. Briakinumab Biosimilar uses the same protein sequences as the therapeutic antibody briakinumab.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human IL-12 / IL-23

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for IL12B (Briakinumab Biosimilar)

Target: IL12B (Briakinumab Biosimilar)

Alternative Name: Briakinumab Biosimilar

Target Type: Biosimilar